These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 34611996)

  • 41. Patient Perspectives and Preferences Regarding Gout and Gout Management: Impact on Adherence.
    Chung MK; Kim SS; Cheon YH; Hong SJ; Choi HJ; Seo MR; Hwang J; Ahn JK; Lee SH; Min HK; Cha HS; Lee SS; Lee J; Moon KW; Lee CK; Kim HO; Suh YS; Shim SC; Kang SW; Kim J; Choi ST; Song JS; Lee J;
    J Korean Med Sci; 2021 Aug; 36(32):e208. PubMed ID: 34402226
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Primary care providers' knowledge, beliefs and treatment practices for gout: results of a physician questionnaire.
    Harrold LR; Mazor KM; Negron A; Ogarek J; Firneno C; Yood RA
    Rheumatology (Oxford); 2013 Sep; 52(9):1623-9. PubMed ID: 23620554
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Gout: an Asia-Pacific update.
    Paul BJ; James R
    Int J Rheum Dis; 2017 Apr; 20(4):407-416. PubMed ID: 28585370
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost-effectiveness of an adherence-enhancing intervention for gout based on real-world data.
    Lin LW; Teng GG; Lim AYN; Yoong JS; Zethraeus N; Wee HL
    Int J Rheum Dis; 2019 Apr; 22(4):545-554. PubMed ID: 30556300
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Patient and clinical characteristics associated with gout flares in an integrated healthcare system.
    Rashid N; Levy GD; Wu YL; Zheng C; Koblick R; Cheetham TC
    Rheumatol Int; 2015 Nov; 35(11):1799-807. PubMed ID: 25991397
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Compounding inequity: a qualitative study of gout management in an urban marae clinic in Auckland.
    Te Karu L; Harwood M; Bryant L; Kenealy T; Arroll B
    J Prim Health Care; 2021 Mar; 13(1):27-35. PubMed ID: 33785108
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost-effectiveness of sequential urate lowering therapies for the management of gout in Singapore.
    Pruis SL; Jeon YK; Pearce F; Thong BY; Aziz MIA
    J Med Econ; 2020 Aug; 23(8):838-847. PubMed ID: 32301360
    [No Abstract]   [Full Text] [Related]  

  • 48. Exploring current and potential roles of Australian community pharmacists in gout management: a qualitative study.
    Counsell AB; Nguyen AD; Baysari MT; Kannangara DRW; McLachlan AJ; Day RO
    BMC Fam Pract; 2018 May; 19(1):54. PubMed ID: 29743018
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Exploratory study of radiographic change in patients with tophaceous gout treated with intensive urate-lowering therapy.
    Dalbeth N; Doyle AJ; McQueen FM; Sundy J; Baraf HS
    Arthritis Care Res (Hoboken); 2014 Jan; 66(1):82-5. PubMed ID: 23836458
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Health literacy in patients dealing with gout: a qualitative study.
    van Onna M; Hinsenveld E; de Vries H; Boonen A
    Clin Rheumatol; 2015 Sep; 34(9):1599-603. PubMed ID: 25501463
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gout is on the increase in New Zealand.
    Klemp P; Stansfield SA; Castle B; Robertson MC
    Ann Rheum Dis; 1997 Jan; 56(1):22-6. PubMed ID: 9059136
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacist-managed titration of urate-lowering therapy to streamline gout management.
    Huang IJ; Liew JW; Morcos MB; Zuo S; Crawford C; Bays AM
    Rheumatol Int; 2019 Sep; 39(9):1637-1641. PubMed ID: 31147732
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Burden and management of gout in a multi-ethnic Asian cohort.
    Chua CKT; Cheung PP; Santosa A; Lim AYN; Teng GG
    Rheumatol Int; 2020 Jul; 40(7):1029-1035. PubMed ID: 31758246
    [TBL] [Abstract][Full Text] [Related]  

  • 54. 2020 recommendations from the French Society of Rheumatology for the management of gout: Urate-lowering therapy.
    Pascart T; Latourte A; Flipo RM; Chalès G; Coblentz-Baumann L; Cohen-Solal A; Ea HK; Grichy J; Letavernier E; Lioté F; Ottaviani S; Sigwalt P; Vandecandelaere G; Richette P; Bardin T
    Joint Bone Spine; 2020 Oct; 87(5):395-404. PubMed ID: 32422338
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis.
    Zhang T; Pope JE
    Rheumatology (Oxford); 2017 Jul; 56(7):1144-1153. PubMed ID: 28379501
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A retrospective analysis of medication prescription records for determining the levels of compliance and persistence to urate-lowering therapy for the treatment of gout and hyperuricemia in The Netherlands.
    Janssen CA; Oude Voshaar MAH; Vonkeman HE; Krol M; van de Laar MAFJ
    Clin Rheumatol; 2018 Aug; 37(8):2291-2296. PubMed ID: 29721712
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Variation in gout care in Aotearoa New Zealand: a national analysis of quality markers.
    Jackson G; Dalbeth N; Te Karu L; Winnard D; Gow P; Gerard C; Minko N
    N Z Med J; 2014 Oct; 127(1404):37-47. PubMed ID: 25331310
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment of tophaceous gout: When medication is not enough.
    Kasper IR; Juriga MD; Giurini JM; Shmerling RH
    Semin Arthritis Rheum; 2016 Jun; 45(6):669-74. PubMed ID: 26947439
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A world of hurt: failure to achieve treatment goals in patients with gout requires a paradigm shift.
    Khanna P; Khanna D; Storgard C; Baumgartner S; Morlock R
    Postgrad Med; 2016 Jan; 128(1):34-40. PubMed ID: 26578028
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Questionnaire survey evaluating disease-related knowledge for 149 primary gout patients and 184 doctors in South China.
    Li QH; Dai L; Li ZX; Liu HJ; Zou CJ; Ou-Yang X; Lu M; Li T; Li YH; Mo YQ; Schumacher HR
    Clin Rheumatol; 2013 Nov; 32(11):1633-40. PubMed ID: 23857664
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.